

Adrienne A Boire

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6716170/publications.pdf>

Version: 2024-02-01

49
papers

4,756
citations

201385

27
h-index

197535

49
g-index

54
all docs

54
docs citations

54
times ranked

6716
citing authors

#	ARTICLE	IF	CITATIONS
1	Leptomeningeal metastatic cells adopt two phenotypic states. <i>Cancer Reports</i> , 2022, 5, e1236.	0.6	26
2	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
3	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	2.3	9
4	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. <i>Neoplasia</i> , 2022, 28, 100790.	2.3	5
5	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	0.6	39
6	Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. <i>Journal of Clinical Oncology</i> , 2022, 40, 3858-3867.	0.8	47
7	Leptomeningeal Metastases: New Opportunities in the Modern Era. <i>Neurotherapeutics</i> , 2022, 19, 1782-1798.	2.1	9
8	Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 134-143.	0.6	56
9	Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 276-283.e3.	7.7	54
10	Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer. <i>Immunity</i> , 2021, 54, 1037-1054.e7.	6.6	56
11	Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 742-752.	1.2	17
12	Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination. <i>Cell Reports</i> , 2021, 35, 109302.	2.9	19
13	Characterization, isolation, and in vitro culture of leptomeningeal fibroblasts. <i>Journal of Neuroimmunology</i> , 2021, 361, 577727.	1.1	5
14	Advances in the diagnosis, evaluation, and management of leptomeningeal disease. <i>Neuro-Oncology Advances</i> , 2021, 3, v86-v95.	0.4	10
15	Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, v181.	0.4	8
16	A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer. <i>Neuro-Oncology</i> , 2020, 22, 675-683.	0.6	39
17	Brain metastasis. <i>Nature Reviews Cancer</i> , 2020, 20, 4-11.	12.8	221
18	Palliation for all people: alleviating racial disparities in supportive care for brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 1239-1240.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. <i>Science</i> , 2020, 369, 276-282.	6.0	146
20	Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. <i>Journal of Neuro-Oncology</i> , 2020, 148, 599-606.	1.4	50
21	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. <i>Cancer Research</i> , 2020, 80, 4314-4323.	0.4	51
22	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 527-541.	1.5	36
23	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249.	13.5	334
24	Molecular Mechanisms in Brain Metastasis. , 2020, , 31-41.		0
25	Metastasis to the Central Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 1584-1601.	0.4	1
26	Leptomeningeal Disease and the Role of Intrathecal Therapy. , 2020, , 169-186.		1
27	Genomic Characterization of a RET Inhibitor-Resistant RET Fusion-Positive Lung Cancer by CSF Cell-Free DNA Hybrid Capture-Based Sequencing. <i>JCO Precision Oncology</i> , 2020, 4, 1361-1366.	1.5	0
28	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	3.2	107
29	Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. <i>Cancer</i> , 2019, 125, 4380-4387.	2.0	51
30	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019, 21, 571-584.	0.6	114
31	Tumour Dormancy and Reawakening: Opportunities and Challenges. <i>Trends in Cancer</i> , 2019, 5, 762-765.	3.8	23
32	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , 2018, 4, 176-196.	3.8	194
33	Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. <i>Nature Cell Biology</i> , 2018, 20, 966-978.	4.6	186
34	Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. <i>Cell</i> , 2017, 168, 1101-1113.e13.	13.5	219
35	Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. <i>Neuro-Oncology</i> , 2017, 19, 1248-1254.	0.6	79
36	Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. <i>Clinical Breast Cancer</i> , 2017, 17, 23-28.	1.1	91

#	ARTICLE	IF	CITATIONS
37	Carcinomaâ€‘astrocyte gap junctions promote brain metastasis by cGAMP transfer. <i>Nature</i> , 2016, 533, 493-498.	13.7	677
38	Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. <i>Journal of Clinical Oncology</i> , 2016, 34, 2404-2415.	0.8	297
39	BM-06 * MECHANISTIC INVESTIGATIONS OF LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS. <i>Neuro-Oncology</i> , 2014, 16, v33-v33.	0.6	2
40	Molecular Interactions in the Development of Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2013, 14, 17157-17167.	1.8	10
41	Targeted therapy in the treatment of malignant gliomas. <i>OncoTargets and Therapy</i> , 2009, 2, 115.	1.0	5
42	Blockade of PAR1 Signaling with Cell-Penetrating Peptides Inhibits Akt Survival Pathways in Breast Cancer Cells and Suppresses Tumor Survival and Metastasis. <i>Cancer Research</i> , 2009, 69, 6223-6231.	0.4	131
43	Platelet Matrix Metalloprotease-1 Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand Site. <i>Cell</i> , 2009, 137, 332-343.	13.5	218
44	Emerging therapies for malignant glioma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, S29-S36.	1.1	13
45	Site-specific Effects of Peptide Lipidation on Î²-Amyloid Aggregation and Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2007, 282, 36987-36997.	1.6	19
46	Spatial Separation of Î²-Sheet Domains of Î²-Amyloid:Â Disruption of Each Î²-Sheet by N-Methyl Amino Acidsâ€. <i>Biochemistry</i> , 2006, 45, 9485-9495.	1.2	42
47	PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells. <i>Cell</i> , 2005, 120, 303-313.	13.5	774
48	Pollen recovery in atmospheric samples collected with the Rotorod Sampler over multiple-day periods such as weekends. <i>Annals of Allergy, Asthma and Immunology</i> , 1999, 83, 217-221.	0.5	9
49	A summary of the atmospheric surveys published in the United States allergy literature, 1966-1996. <i>Annals of Allergy, Asthma and Immunology</i> , 1999, 82, 543-547.	0.5	6